Bayer on Thursday provided additional data on late-stage studies of its rival drug to Astellas’ Veozah, which met all primary ...

GSK said Thursday it plans to divest its remaining 4.2% stake in the consumer health spinout, its fourth and final round of ...

Bolstered by promising response data from its Phase II study, Amgen announced Thursday it got the FDA’s green light for its first-in-class bi-specific T-cell engager Imdelltra for extensive-stage ...

Since taking the helm in 2023, Anderson has embarked on a radical departure from the traditional structure of large pharma ...

Roche’s $2.7 billion acquisition of Carmot Therapeutics in December 2023 appears to be paying off as its investigational ...

Eli Lilly’s efsitora alfa, which is meant to be taken weekly instead of multiple times a day, demonstrated non-inferior A1C ...

A Senate health committee report published Wednesday forecasts spending on prescription drugs may hit $1 trillion a year in ...

The European Medicines Agency on Friday recommended withdrawing approval for a drug used to prolong gestation due to the lack ...

Belgian biotech Galapagos is teaming with Blood Centers of America to help deploy its decentralized CAR-T therapy ...

Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, ...

With Monday’s agreement, AbbVie joins the industry’s growing interest in psychedelic therapies and looks to leverage ...

While biopharma professionals cited age discrimination as an issue in a new BioSpace report, it’s not the only factor ...